Hydrochloorthiazide Teva

Hydrochlorothiazide Teva is an oral tablet containing the thiazide diuretic hydrochlorothiazide; the specific strength and dosage form are not disclosed in the available data. Marketed in the European Union, this prescription‑only medication belongs to the antihypertensive therapeutic class and is used to manage fluid retention and high blood pressure under medical supervision. It is produced by Teva and is prescribed for adults as part of a comprehensive hypertension management plan.

Hydrochlorothiazide Teva is indicated for several conditions where reduction of excess fluid or blood pressure is required.

- Hypertension (high blood pressure), either alone or combined with other antihypertensive agents. - Edema linked to congestive heart failure, helping to reduce fluid overload. - Fluid accumulation caused by liver cirrhosis, including ascites management. - Renal disease‑related edema such as that seen in nephrotic syndrome. - Prevention of recurrent ascites in patients with advanced liver disease. - Adjunct therapy for resistant hypertension when additional blood‑pressure control is needed.

Like other thiazide diuretics, Hydrochlorothiazide Teva may cause a range of adverse reactions, most of which are mild and reversible.

Common: - Increased urination (polyuria) and mild thirst. - Low blood potassium (hypokalemia) leading to muscle cramps or fatigue. - Elevated blood glucose levels, especially in diabetic patients. - Dizziness or light‑headedness due to reduced blood pressure. - Mild increase in blood uric acid, which can precipitate gout.

Serious: - Severe electrolyte disturbances such as hyponatremia or hyperkalemia. - Acute kidney injury manifested by sudden rise in serum creatinine. - Allergic reactions including rash, pruritus, or angioedema. - Pancreatitis, indicated by abdominal pain and elevated enzymes. - Blood disorders such as leukopenia or thrombocytopenia.

When prescribing Hydrochlorothiazide Teva, clinicians should evaluate patient history and monitor laboratory values to minimize risks.

- Assess renal function before initiation and periodically during therapy. - Monitor serum electrolytes, especially potassium and sodium, to detect imbalances. - Use caution in patients with a history of gout or hyperuricemia. - Evaluate blood glucose levels in diabetic individuals, as the drug may raise glucose. - Consider potential photosensitivity; advise patients to limit excessive sun exposure. - Review concomitant use of other diuretics or antihypertensives to avoid excessive volume depletion. - Avoid use in patients with known hypersensitivity to thiazide diuretics.

Hydrochlorothiazide Teva can interact with several medicines, altering its diuretic effect or increasing the risk of adverse events.

Avoid: - Combined use with other potent diuretics (e.g., loop diuretics) that may cause severe electrolyte loss. - Concurrent administration of lithium, which can raise lithium concentrations and toxicity risk. - Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt diuretic efficacy and impair renal function.

Use with caution: - ACE inhibitors or ARBs, which together can increase the likelihood of hyperkalemia. - Antidiabetic agents, as thiazides may enhance hypoglycemic effects. - Anticoagulants, because volume depletion can affect drug plasma levels. - Calcium channel blockers, which may augment antihypertensive response.